Benzinga | Feb 17, 2021 12:01PM EST

Cowen & Co. Maintains Outperform on Exact Sciences, Raises Price Target to $180

Cowen & Co. analyst Doug Schenkel maintains Exact Sciences (NASDAQ:EXAS) with a Outperform and raises the price target from $154 to $180.